BASF tells Pronova shareholders enough already; GSK still fighting for wind turbines;

> BASF has upped its offer for buying Pronova BioPharma to €684 million ($910 million) from €644 million ($856.8 million) but reminds them the deadline is Friday and says that is as high as it will go for the maker of omega-3 products. Story

> Serum Institute of India has started construction of a new manufacturing plant that will be dedicated to the production of CRM197 for Pfenex Reagent Proteins. Item

> The European Medicines Agency is taking comment on draft guidance about how manufacturers can avoid cross-contamination of drugs. Release (pdf)

> GE Healthcare is seeking permission from the FDA to manufacture its imaging agent Optison at its own plant in Oslo, Norway. Item

> Swiss contract manufacturer Lonza is giving BaroFold's PreEMT high-pressure protein refolding technology a test run at its plant in Visp. Release

And Finally... GlaxoSmithKline ($GSK) continues to face opposition from the town of Montrose, Scotland, to erecting two wind turbines to provide more environmentally responsible energy for a new plant there. Item

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.